Methods and compositions for identifying and treating subjects at risk for checkpoint blockade therapy associated colitis
The present invention relates to methods and compositions for identifying subjects treated with or considered for treatment with checkpoint blockade therapeutic agents that are at higher or lower risk for developing checkpoint therapy associated colitis, by analyzing the intestinal microbiome of those subjects. It is based, at least in part, on the discovery that the abundance of certain intestinal microbiota of the phyla Bacteroidetes, including the bacteria in the families Bacteroidaceae, Rikenellaceae, and Barnesisllaceae, and/or an increase or decrease in microbial genetic pathways involved in polyamine transport and/or B vitamin biosynthesis (e.g., (riboflavin (B2), pantothenate (B5) and thiamine (B1)) are associated with the likelihood of developing checkpoint therapy associated colitis.
1. A pharmaceutical composition for reducing the risk or severity of checkpoint blockade therapy-associated colitis comprising isolated bacteria or spores thereof comprising (i) a member of the Bacteroidaceae family and (ii) a member of the Barnesiellaceae family, and further comprising:
(a) a biocompatible pharmaceutical carrier selected from saline, buffered saline, dextrose, glycerol and polyethylene glycol;
(b) an additional therapeutic agent selected from a probiotic, a prebiotic, a postbiotic and an antibiotic;
(c) a solubilizer; or
(d) a preservative,
wherein the pharmaceutical composition is formulated for oral, nasogastric or rectal administration, and
wherein the isolated bacteria or spores thereof are present in a therapeutically effective amount that reduces the risk or severity of checkpoint blockade therapy-associated colitis in a subject administered the pharmaceutical composition.
2. The pharmaceutical composition of claim 1 , further comprising an isolated bacteria or spores thereof of a member of the Rikenellaceae family.
3. The pharmaceutical composition of claim 1 , wherein one or more of the isolated bacteria is a recombinant cell.
4. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is a liquid, suspension, dried powder, tablet, capsule or food product.
5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further comprises a probiotic bacteria, probiotic yeast, or a combination thereof; a prebiotic; a postbiotic; an antibiotic; or combination thereof.
6. The pharmaceutical composition of claim 1 , wherein one or more of the isolated bacteria or spores thereof are lyophilized.